Impax Laboratories (IPXL) Tops Q4 EPS by 4c

Impax Laboratories (NASDAQ: IPXL) reported Q4 EPS of $0.16, $0.04 better than the analyst estimate of $0.12. Revenue for the quarter came in at $131.2 million versus the consensus estimate of $125.5 million.

For earnings history and earnings-related data on Impax Laboratories (IPXL) click here.

You May Also Be Interested In

• JPMorgan Upgrades Aviva Plc (AV/:LN) (AIVAF) to Overweight
• Axis Capital Limited Downgrades National Aluminium (NACL:IN) to Sell (4)
• Hyperion DeFi (HYPD) Tops Q2 EPS by 57c